Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients
Table 1
Demographic and clinical characteristics of 178 HIV patients.
Parameter
HAART
Naïve
Total
P value
Number
104 (58.4%)
74 (41.6%)
178
Age (years)
50.18 10.19
46.68 11.64
48.72 10.92
0.34
Sex
0.829
Males ()
90 (86.5%)
63 (85.1%)
153
Females ()
14 (13.5%)
11 (14.9%)
25
HIV transmission category
0.368
Blood
1 (1.0%)
1 (1.4%)
2
IVDU
2 (1.9%)
1 (1.4%)
3
MSM
69 (66.3%)
47 (63.5%)
116
Sexual transmitted
16 (15.4%)
18 (24.3%)
34
Unknown
16 (15.4%)
7 (9.5%)
23
CDC stage
<0.001
A
57 (54.8%)
19 (25.7%)
76 (42.7%)
B
37 (35.6%)
31 (41.9%)
68 (38.2%)
C
10 (9.6%)
24 (32.4%)
34 (19.1%)
1.06 1.64
4.12 1.82
2.33 2.29
<0.001
CD4
547 305
392 319
483 319
0.001
CD4 nadir
371 225
293 220
339 226
0.499
HIV infection duration (years)
14.81 7.21
7.81 5.26
11.90 7.33
<0.001
Thyroid function
0.037
Normal
63 (60.6%)
56 (75.7%)
119 (66.9%)
Abnormal
41 (39.4%)
18 (24.3%)
59 (33.1%)
Subhypothyroidism
9 (8.7%)
3 (4.1%)
12 (6.6%)
Overt hypothyroidism
28 (26.9%)
12 (16.2%)
40 (22.1%)
Overt hyperthyroidism
4 (3.8%)
3 (4.1%)
7 (3.9%)
HAART, HIV patients receiving highly active antiretroviral therapy (HAART); naïve: HAART naïve HIV patients; IVDU, intravenous drug user; MSM, men who have sex with men; VL: viral load.
